We present a case of medication-induced akathisia in a 47-year-old woman with metastatic carcinoma of the ovary. Severe pacing and restlessness started after commencing a subcutaneous infusion with cyclizine 150mg, haloperidol 2.5 mg and oxycodone 20 mg. She was also taking levomepromazine and fluoxetine orally at the time. By making changes to her medication, her symptoms resolved gradually. During the time of convalescence, she gained great symptomatic relief from using exercise pedals and it allowed her to go about usual everyday activities, such as eating and reading, while continuously treading the pedals. Palliative Medicine 2007;21 : 713—715
Hamilton MS , Opler LAAkathisia, suicidality, and fluoxetine . J Clin Psychiatry1992; 53(11): 401—6 .
2.
Lane RMSSRI-induced extrapyramidal side-effects and akathisia: implications for treatment . J Psychopharmacol1998; 12(2): 192—214 .
3.
Janno S. , Holi M. , Tuisku K. , Wahlbeck K.Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients . Am J Psychiatry2004; 161(1): 160—3 .
4.
Kim JH , Byun HJPrevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects . Clin Neuropharmacol2003; 26(6): 312—6 .
5.
Gattera JA , Charles BG , Williams GM , Cavenagh JD , Smithurst BA , Luchjenbroers J.A retrospective study of risk factors of akathisia in terminally ill patients . J Pain Symptom Manage1994; 9(7): 454—61 .
6.
JointFormulary Committee. British national formulary, 51st edition. British Medical Association and Royal Pharmaceutical Society of Great Britain , 2006.
7.
Holley FO , Magliozzi JR , Stanski DR , Lombrozo L. , Hollister LEHaloperidol kinetics after oral and intravenous doses . Clin Pharmacol Ther1983; 33(4): 477—84 .
8.
Magliozzi JR , Hollister LEElimination half-life and bioavailability of haloperidol in schizophrenic patients . J Clin Psychiatry1985; 46(1): 20—1 .
9.
Darby JK , Pasta DJ , Dabiri L. , Clark L. , Mosbacher D.Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting . J Clin Psychopharmacol1995 ; 15(5): 334—40 .
10.
Froemming JS , Lam YW , Jann MW , Davis CMpharmacokinetics of haloperidol . Clin Pharmacokinet1989; 17(6): 396—423 .
11.
Caley CFExtrapyramidal reactions and the selective serotonin-reuptake inhibitors . Ann Pharmacother1997; 31(12): 1481—9 .
12.
Leo RJMovement disorders associated with the serotonin selective reuptake inhibitors . J Clin Psychiatry1996; 57(10): 449—54 .
13.
Lal S. , Nair NP , Cecyre D. , Quirion R.Levomepromazine receptor binding profile in human brain—implications for treatment-resistant schizophrenia . Acta Psychiatr Scand1993; 87(6): 380—3 .
14.
Eisenchlas JH , Garrigue N. , Junin M. , De Simone GGLow-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study . Palliat Med2005; 19(1): 71—5 .
15.
Kennett A. , Hardy J. , Shah S. , A'Hern R.An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer . Supp Care Cancer2005; 13(9): 715—21 .
16.
Skinner J. , Skinner A.Levomepromazine for nausea and vomiting in advanced cancer . Hosp Med1999; 60(8): 568—70 .
17.
Hansen L.A critical review of akathisia, and its possible association with suicidal behaviour . Hum Psychopharmacol2001; 16(7): 495—505 .
18.
Lima AR , Bacalcthuk J. , Barnes TR , Soares-Weiser K.Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia . Cochrane Database Syst Rev2004 ; (4): CD001946.
19.
Lima AR , Weiser KV , Bacaltchuk J. , Barnes TRAnticholinergics for neuroleptic-induced acute akathisia . Cochrane Database Syst Rev2004; (1): CD003727.
20.
Poyurovsky M. , Epshtein S. , Fuchs C. , Schneidman M. , Weizman R. , Weizman A.Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study . J Clin Psychopharmacol2003; 23(3): 305—8 .
21.
Poyurovsky M. , Pashinian A. , Weizman R. , Fuchs C. , Weizman A.Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial . Biol Psychiatry2006; 59(11): 1071—7 .
22.
Ranjan S. , Chandra PS , Chaturvedi SK , Prabhu SC , Gupta A.Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine (April) . Ann Pharmacother2006 ; 40(4): 771—4 .
23.
He N. , Zhang WQ , Shockley D. , Edeki T.Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes . Eur J Clin Pharmacol2002; 57(12): 847—51 .
24.
Suzuki A. , Yasui-Furukori N. , Mihara K. , Kondo T. , Furukori H. , Inoue Y. , Kaneko S. , Otani K.Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. ThereDrug Monit2003; 25(2): 192—6 .
